A twice-daily formulation of Austedo was first authorized in the U.S. back in 2017. In early 2023, the Israeli drugmaker won FDA clearance for Austedo XR to market its extended-release version at ...

Central to its near-term growth plan is the performance of Austedo (deutetrabenazine), approved for Huntington’s disease and tardive dyskinesia, which Teva predicts will bring in $2.5 billion in ...

The FDA has approved Austedo (deutetrabenazine) tablets for the treatment of chorea associated with Huntington’s disease (HD). Formerly known as SD-809, Austedo is the first drug containing ...

FDA recently awarded new chemical entity (NCE) exclusivity to Austedo™ (deutetrabenazine). The Austedo approval is notable for two reasons: One, it is the first deuterated drug (i.e., a drug ...

Lawmakers seek balance between lower prescription drug prices, drug innovation incentives Austedo, a brand-name drug from Teva that treats neurological diseases, is a candidate for the next round ...